Procept Biorobotics Corp

A securities fraud class action has been filed against PROCEPT BioRobotics Corporation after revelations that the company used undisclosed bulk discounts to inflate handpiece sales, leading to a 48% stock decline. The lawsuit, filed by Hagens Berman Sobol Shapiro LLP, represents investors who purchased PROCEPT common stock between February 28, 2024 and February 25, 2026. The complaint alleges that PROCEPT incentivized customers to place bulk orders exceeding actual procedure demand, pulling forward sales and artificially boosting reported revenues. Investors learned the truth through a series of disclosures starting August 6, 2025, when handpiece sales missed estimates, culminating on February 25, 2026, when the company revealed cumulative excess customer inventory of over 10,000 units and a 30% sequential drop in U.S. handpiece sales. The lead plaintiff deadline is September 22, 2026.

PROCEPT BioRobotics lowered its 2026 U.S. procedure guidance to a range of 54,000 to 56,000, down from the prior 60,000 to 64,000, while reiterating full-year revenue guidance of $390 million to $410 million and maintaining its expectation for positive adjusted EBITDA in the fourth quarter of 2026. The company reported second-quarter total revenue of $94.5 million, a 19% year-over-year increase, with U.S. revenue of $83.4 million and international revenue of $11.1 million. U.S. procedures grew 21% to over 13,100, but fell short of expectations due to concentrated softness in legacy AQUABEAM accounts, prompting an accelerated push to upgrade those systems to HYDROS. PROCEPT placed 65 HYDROS systems during the quarter at an average selling price of approximately $495,000, up from $485,000 in the first quarter, and recorded a net loss of $26.9 million with an adjusted EBITDA loss of $11.3 million. Management expects to complete roughly 40 replacement sales at the midpoint of its revenue guidance, with replacement system pricing of $300,000 to $325,000, and sees the replacement cycle remaining a significant factor into 2027.

The Law Offices of Howard G. Smith reminds investors of upcoming lead plaintiff deadlines in securities fraud class actions against Procept BioRobotics Corporation, Photronics, Inc., Peabody Energy Corporation, and Wix.com Ltd. For Procept BioRobotics, the class period runs from February 28, 2024 to February 25, 2026, with a lead plaintiff deadline of September 22, 2026; the complaint alleges the company used an undisclosed discount program that artificially inflated handpiece sales and created over 10,000 excess units in field inventory. Photronics faces a class period from December 10, 2025 to May 27, 2026 and a September 4, 2026 deadline, with allegations of undisclosed bottlenecks in its high-end chip design release pipeline. Peabody Energy's class period spans October 14, 2024 to May 4, 2026, with an August 24, 2026 deadline, and the complaint claims the company made overly optimistic statements about the Centurion mine ramp-up that fell short of reality. Wix.com's class period is February 19, 2025 to May 12, 2026, with a September 22, 2026 deadline, and the complaint alleges the company overstated the competitiveness and benefits of its AI product offerings while understating associated costs. Investors who suffered losses may contact the firm to discuss their legal rights.

Glancy Prongay Wolke & Rotter LLP reminds investors that the deadline to file a lead plaintiff motion in the class action against Procept BioRobotics Corporation is September 22, 2026. The lawsuit covers investors who purchased or acquired Procept securities between February 28, 2024 and February 25, 2026. The complaint alleges that the company used an undisclosed discount program that artificially inflated U.S. handpiece sales, leading to more than 10,000 excess units in field inventory and a nearly 30% decline in fourth-quarter U.S. handpiece sales. Procept's stock price fell on multiple disclosures, including a 15.12% drop to $23.63 on February 26, 2026, after revealing the excess inventory and the elimination of the discount program.

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of Wix.com, PROCEPT BioRobotics, and Rackspace Technology, with lead plaintiff deadlines in September 2026. The Wix.com class action covers a class period from February 19, 2025 to May 12, 2026 and alleges the company overstated the competitiveness and benefits of its AI product offerings while understating associated costs. The PROCEPT BioRobotics suit, with a class period from February 28, 2024 to February 25, 2026, claims the company used an undisclosed discount program that artificially inflated handpiece sales and created over 10,000 excess units in field inventory. The Rackspace Technology class action, spanning May 7, 2026 to July 8, 2026, alleges the company failed to disclose that its enterprise AI pivot would divert capacity from its profitable Private Cloud segment and that a material reduction in its Public Cloud resale business would significantly impact fiscal year 2026 revenue.

Multiple securities law firms, including Robbins Geller Rudman & Dowd LLP and Rosen Law Firm, have filed class action lawsuits against PROCEPT BioRobotics, alleging the company used undisclosed bulk-order discounting that inflated reported U.S. handpiece sales and conflicted with prior guidance between February 2024 and February 2026. The lawsuits claim the discount program pulled sales forward, left more than 10,000 excess handpiece units in the field, and exposed investors to previously undisclosed operational and financial risks tied to inventory imbalances. These allegations could reshape the investment narrative for PROCEPT BioRobotics, which previously projected $608.2 million in revenue and $77.8 million in earnings by 2029, requiring 23.6% annual revenue growth and a $180.3 million earnings improvement from a current loss of $102.5 million. The legal overhang adds uncertainty around reported growth quality, future guidance, and how quickly Aquablation usage can normalize once field inventory is addressed.

A securities fraud class action has been filed against PROCEPT BioRobotics Corporation, and investors have until September 22, 2026 to seek lead plaintiff appointment. The lawsuit, pending in the U.S. District Court for the Northern District of California, alleges the company artificially inflated its financial performance through an extensive discount program that encouraged bulk handpiece orders far exceeding actual procedures. The complaint points to a cumulative excess field inventory of more than 10,000 units and a roughly 30% contraction in U.S. handpiece unit sales disclosed in February 2026, which contributed to an 18% stock drop over two trading days. Earlier disclosures in August and November 2025 also triggered declines of 16% and 10%, respectively. The law firm Bleichmar Fonti & Auld LLP is encouraging affected investors to contact them regarding potential claims on a contingency fee basis.